Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Jayjayton Aug 15, 2020 8:04am
169 Views
Post# 31412101

RE:Key take away from interview - GVHD handover clarification

RE:Key take away from interview - GVHD handover clarification
we have been screwed by kaly. If we vote no for the acquisition . So we have no compagny, no product. If my understandingis correct. .. Someone have To pay for our investment. Guys wake up. Th talent take it back. So de invested for them To be honest we will probably not take it forward. Were basically turning it back over to the Israeli group we bought it off of. I know its a big disappointment to our shareholders as it is for us as the data showed that the product worked in the prevention of GVHD. But, as you know, the reasons for this move were many - as you and I have spoken at length about it before. (reasons were the cost of phase three which would require a larger pharma company taking the project over and, lacking the large market size they require as well as the CBD association made it a less than attractive opportunity for them.)
<< Previous
Bullboard Posts
Next >>